Market News AIOpen the app

Rezolute, Inc. has signed a deal to sell about 22 million shares, expecting to raise around $93.5 million.

New sharesRead the original at SEC EDGAR
Bad for RZLT

Rezolute expects about $94 million after costs to prepare for ersodetug sales, but the share sale and warrants can add shares. This shrinks each current owner's portion, making the deal unfavorable for them despite the cash.

RZLT · Rezolute, Inc.

AI read · Bad for RZLT

The AI's read

The proceeds can help pay for ersodetug sales preparation and other company needs. That gives Rezolute cash to keep moving toward selling the drug. The new stock means current owners will own a smaller part of Rezolute. The pre-funded warrants can add shares for $0.001 each if exercised, shrinking their portions further. This cost to owners outweighs the benefit of added cash. The sale is expected to close around November 16, subject to customary closing conditions.

Get alerts for RZLT

Follow Rezolute, Inc. (RZLT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for RZLT
Free on the App Store and Google Play, or on the web.